A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.

Jackson, G; Taylor, P; M Smith, G; Marcus, R; Smith, A; Chu, P; J Littlewood, T; Duncombe, A; Hutchinson, M; B Mehta, A; A Johnson, S; Carey, P; J MacKie, M; S Ganly, P; E Turner, G; Deane, M; Schey, S; Brookes, J; M Tollerfield, S; P Wilson, M

doi:10.1046/j.1365-2141.2001.02551.x

Public

A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.

Published in British journal of haematology • Jan 1, 2001

NobleIDark:/48914/w1/20260522/D6DF6F57Record on NobleID

Authors:

G Jackson

,

P Taylor

,

G M Smith

Abstract

The primary objective of this study was to determine the complete remission (CR) rate achieved with the FLAG (fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor) regimen in patients with relapsed or refractory acute myeloid leukaemia (AML) or de novo refractory anaemia with ...

Discussions